
MCCAIG/E+ via Getty Images
Halozyme (NASDAQ:HALO) stock rose on Wednesday after the company raised 2025 guidance, prompting a rating upgrade by Morgan Stanley.
The company raised 2025 revenue in the range between $1,275M and $1,355M, from previous range between $1,200M to $1,280M, compared to consensus of $1.25B.